Open-Label Study of Pocenbrodib Alone and in Combination With Abiraterone Acetate, Olaparib, or 177Lu-PSMA-617
Conditions
- mCRPC (Metastatic Castration-resistant Prostate Cancer)
- Genital Neoplasms, Male
- Urogenital Neoplasms
- Urogenital Cancers
- Prostatic Diseases
- Prostatic Neoplasms
- Male Urogenital Diseases
- Neoplasms
- Neoplasms by Site
- Prostate Cancer
Interventions
- DRUG: Pocenbrodib
- DRUG: Cohort 2A (Pocenbrodib monotherapy), Cohort 2B (Pocenbrodib + abiraterone acetate), Cohort 2C (Pocenbrodib + olaparib), Cohort 2D (Pocenbrodib + 177Lu-PSMA-617
Sponsor
Pathos AI, Inc.
Collaborators